Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
María J Moro-Álvarez1, Manuel Díaz-Curiel21Hospital Central Cruz Roja, Madrid, 2Fundación Jiménez Díaz, Madrid, Spain, Internal Medicine, Metabolic Bone Disease UnitAbstract: Postmenopausal osteoporosis increases susceptibility to low...
Saved in:
Main Authors: | María J Moro-Álvarez, Manuel Díaz-Curiel |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2008
|
Subjects: | |
Online Access: | https://doaj.org/article/2c92af5d20584aba942b4444933a767c |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
by: Paula Rackoff
Published: (2009) -
Review of the safety and efficacy of risedronate for the treatment of male osteoporosis
by: Raja Bobba, et al.
Published: (2007) -
Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
by: Irene Lambrinoudaki, et al.
Published: (2008) -
Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
by: Philip Sambrook
Published: (2007) -
Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice
by: Oliver Bock, et al.
Published: (2008)